CS060380

DRUG3 trials

Sponsors

Cascade Pharmaceuticals, Inc

Conditions

MASHMetabolic Dysfunction-associated Steatohepatitis (MASH)NASHObesity

Phase 1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

CompletedNCT06573528

Cascade Pharmaceuticals, IncMASH

Start: 2024-09-03End: 2025-05-21Updated: 2025-08-13

Phase 2

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

RecruitingNCT07198386

Cascade Pharmaceuticals, IncNASH

Start: 2025-09-30End: 2026-11-30Target: 120Updated: 2026-03-13

A Study of CS060380 Tablets in Patients With MASH and Obesity

Active, not recruitingNCT07466017

Cascade Pharmaceuticals, IncMetabolic Dysfunction-associated Steatohepatitis (MASH), Obesity

Start: 2026-04-02End: 2027-07-30Updated: 2026-08-10